Sinovac Biotech (北京科兴生物制品有限公司) reported that revenues from its vaccines rose 39% in 2008 to $46.5 million, while net income increased by a relatively small 5% to $8 million. A full 88% of the company’s 2008 sales came from Healive®, its hepatitis A vaccine that has long been Sinovac’s mainstay product. Sinovac said it expects 2009 revenues to increase a further 20% to a range of $55 million to $60 million. More details...

Stock Symbol: (NYSE Amex: SVA)